The principal pharmacodynamic effect of peppermint oil relevant to the gastrointestinal tract is a dose-related antispasmodic effect on the smooth musculature due to the interference of menthol with the movement of calcium across the cell membrane. The choleretic and antifoaming effects of peppermint oil may play an additional role in medicinal use. Peppermint oil is relatively rapidly absorbed after oral administration and eliminated mainly via the bile. The major biliary metabolite is menthol glucuronide, which undergoes enterohepatic circulation. The urinary metabolites result from hydroxylation at the C-7 methyl group at C-8 and C-9 of the isopropyl moiety, forming a series of mono- and dihydroxymenthols and carboxylic acids, some of which are excreted in part as glucuronic acid conjugates. Studies with tritiated I-menthol in rats indicated about equal excretion in feces and urine. The main metabolite indentified was menthol-glucuronide. Additional metabolites are mono- or di-hydroxylated menthol derivatives.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phymed.2004.10.007DOI Listing

Publication Analysis

Top Keywords

peppermint oil
16
pharmacology preclinical
4
preclinical pharmacokinetics
4
peppermint
4
pharmacokinetics peppermint
4
oil
4
oil principal
4
principal pharmacodynamic
4
pharmacodynamic peppermint
4
oil relevant
4

Similar Publications

Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of an essential oil from the aerial parts of  ×  L. (peppermint oil) when used as a sensory additive in feed and in water for drinking for all animal species. The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) concluded that that peppermint oil is safe for all animal species at the maximum use level of 12 mg/kg complete feed.

View Article and Find Full Text PDF
Article Synopsis
  • Tyrosine kinase inhibitors like tofacitinib (TCB) are effective in treating psoriasis, and this study aims to enhance TCB's effectiveness while minimizing side effects through a new topical emulgel formulation.
  • The emulgel was created by combining TCB with various ingredients, resulting in a formulation with ideal viscosity, firmness, and controlled release of the drug over 24 hours.
  • The new TCB-emulgel showed significantly improved anti-psoriatic effects in a mouse model, reducing psoriasis severity scores and inflammation markers compared to existing treatments, supporting its potential for clinical use in managing psoriasis.
View Article and Find Full Text PDF

Adjunct Therapies to Standard Care for IBS and IBD Patients: Digestive Symptoms Improvement and Quality of Life Optimization.

Nutrients

November 2024

RNI-Product-Life Group, RNI Conseil, 17 Rue des 2 Haies, 49100 Angers, France.

The prevalence of both inflammatory bowel diseases (IBD) and Irritable Bowel Syndrome (IBS) is increasing, with persistent digestive symptoms, an altered quality of life, and higher rates of anxiety, chronic fatigue, and sleep trouble than the general population. This scoping review will analyze the latest clinical practice recommendations and clinical studies on non-pharmaceutical interventions such as diet adaptations, physical activity, cognitive behavioral therapies, and medical nutrition therapies such as probiotics, soluble fibers, chitin-glucan, and micronutrients for digestive symptoms relief, quality of life improvement and nutritional deficiencies correction in IBS and IBD patients. The objective is to help healthcare practitioners and dietitians to build personalized care program for IBD and IBS patients.

View Article and Find Full Text PDF

Gastric cancer (GC) represents one of the most lethal forms of cancer. When identified at an early stage, conventional treatment can be curative. The key to identifying GC at an early stage is high-quality esophagogastroduodenoscopy (EGD).

View Article and Find Full Text PDF

Androgenetic alopecia is a chronic dermatological condition in which genetically predisposed individuals undergo progressive hair loss secondary to the effects of circulating androgens. It has been well documented that dihydrotestosterone binds to the androgenic receptors prevalent in the scalp, thus inducing miniaturization of the hair follicle. To date, the only FDA approved medications for the treatment of androgenetic alopecia are finasteride and minoxidil.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!